Theratechnologies Announces Financial Results For Fiscal Year 2019

Feb 25, 2020
PDF Version
Supporting Materials:

Montreal, Canada – February 25, 2020 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced its financial results for the year ended November 30, 2019.

Fiscal Year 2019 Financial Highlights

  • Record revenue with net sales of US$63,216,000, up 39.8% from the previous year
  • Trogarzo® sales reach US$27,696,000, up 212% from the previous year
  • EGRIFTA® sales reach US$35,520,000, down 2.2% from the previous year
  • Strong cash position of US$41,244,000

“Our last fiscal year was one of many accomplishments. In the last twelve months, we managed to obtain approval for Trogarzo® in Europe, to launch a new formulation of tesamorelin, EGRIFTA SVTM, to list our shares on NASDAQ, to grow our revenues by 40 percent, to acquire a unique and highly-promising technology platform in oncology, to launch the development program of tesamorelin for the treatment of NASH in HIV and to manage to record a slightly positive EBITDA while investing in Europe and in our developments programs,” said Luc Tanguay, President and CEO, Theratechnologies Inc.

“We ended the year with a company stronger than ever and with tools to sustain growth through our commercialized products and a promising pipeline,” added Mr. Tanguay.